Market Access | Getting therapies in patients' hands

News

Expanded US Imaavy approval first ever for wAIHA

The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).

News

EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe

Acadia Pharmaceuticals has secured EC approval for DAYBU (trofinetide) for the neurobehavioural symptoms of Rett syndrome in the EU.

News

Japan first approval for GSK’s bepirovirsen for CHB

Japan has approved GSK's antisense oligonucleoide Hibsago (bepirovirsen) as a functional cure in chronic hepatitis B virus infection in adult patients

News

UK MHRA authorises orforglipron private prescription

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

News

Trump taps White House aide Heidi Overton to lead FDA

US President Donald Trump has nominated White House health policy aide Heidi Overton to take up the mantle of FDA commissioner.

News

NICE backs NHS funding for MSD's Keytruda combination in lun...

NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with pemetrexed and platinum chemotherapy in certain lung cancer patients.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J asks FDA for emergency clearance for single-shot COVID-1...

Johnson & Johnson’s Janssen unit has filed its single dose COVID-19 vaccine candidate with the FDA, asking for an Emergency Use Authorization (EUA).

Views & Analysis

Achievement-so-far-on-objective-on-affordability

VPAS: Achievements so far on affordability

In the second part of this series taking stock of

News

As drug costs for US employers rise, some cut GLP-1s from pl...

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and nontraditional PBMs to cut costs.

News

Expanded US Imaavy approval first ever for wAIHA

The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

Views & Analysis

Market Access

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

Deep Dive

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

Market Access

The expanding role of early-phase trials in modern drug deve...

Market Access

Market Access 2026

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and en

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Video

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

Consolidating data strategy for global success: Insights fro...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Partner Content

The MFN effect: what payers expect and how Pharma should res...

A live webinar and audience Q&A with practical insights from global payer research and leading payer experts

Event

Partner Content

The Pharmaceutical Launch Excellence Summit

Where pharma leaders share strategies for successful drug launches.

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Event

Partner Content

The MFN effect: what payers expect and how Pharma should res...

A live webinar and audience Q&A with practical insights from global payer research and leading payer experts

Event

Partner Content

The Pharmaceutical Launch Excellence Summit

Where pharma leaders share strategies for successful drug launches.

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks